Prosteria - National Trends and Outcomes of More Frequent than Guideline Recommended Prostate Specific Antigen Screening.

To characterize national trends in and associated outcomes of more often than annual PSA screening, which we term "prosteria".

Men in the Optum Clinformatics® Data Mart with ≥ 2 years from first PSA test to censoring at the end of insurance or available data (January 2003 to June 2019) or following exclusionary diagnoses or procedures, such as PCa treatment, were included. PSAs within 90 days were treated as one PSA. Prosteria was defined as having ≥3 PSA testing intervals of ≤270 days.

9,734,077 PSAs on 2,958,923 men were included. The average inter-PSA testing interval was 1.5 years, and 4.5% of men had prosteria, which increased by 0.53% per year. Educated, wealthy, non-White patients were more likely to have prosteria. Men within the recommended screening age (i.e. 55-69) had lower rates of prosteria. Prosteria patients had higher average PSA values (2.5 vs 1.4 ng/ml), but lower values at PCa diagnosis. Prosteria was associated with biopsy and PCa diagnosis; however, there were comparable rates of treatment within 2 years of diagnosis.

In this large cohort study, prosteria was common, increased over time, and was associated with demographic characteristics. Importantly, there were no clinically meaningful differences in PSA values at diagnosis or rates of early treatment, suggesting prosteria leads to both overdiagnosis and overtreatment. These results support current AUA and USPTF guidelines and can be used to counsel men seeking more frequent PSA screening.

Urology. 2023 Jan 25 [Epub ahead of print]

Dylan J Peterson, Hriday P Bhambhvani, David R W Baird, Shufeng Li, Michael L Eisenberg, James D Brooks

Department of Urology, Stanford University School of Medicine, Palo Alto, CA. Electronic address: ., Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, NY., Department of Urology, Stanford University School of Medicine, Palo Alto, CA.